The company is a leading integrated pharmaceutical group specializing in traditional Asian medicine, chemical medicine, and biopharmaceutical products. It operates multiple subsidiaries and is recognized as a top innovator with state-of-the-art research facilities, including national engineering and technology centers. The company collaborates with over 100 research institutions globally and has received prestigious national awards for technological innovation and scientific progress. It maintains high standards of quality with certifications from ICH, FDA, and EDQM, and has passed national GMP authentication. The company focuses on innovation and service, aiming to strengthen its position in chemical pharmaceuticals, traditional Asian medicine, and biopharmaceuticals.

The company is an innovative pharmaceutical enterprise engaged in international competition, focusing on complex formulations, unique APIs, generics, and original new drugs to address unmet clinical needs globally. It has developed advanced drug technology platforms, including fermentation semi-synthesis, multi-chiral drug development, non-biological macromolecule production, drug-device combinations, and coupling drugs. The company specializes in therapeutic areas such as antifungal, antiviral, immunosuppression, oncology, cardiovascular, respiratory, and iron supplementation. Certified by GMP standards in China, the U.S., the EU, Japan, and South Korea, the company’s products are marketed worldwide, supported by a robust R&D foundation, global registration, and a comprehensive cGMP production system.